(MENAFN) A US biotech company pioneering tablets containing embedded microchips that can tell if patients have taken their medication said it has raised a further USD172 million, including funds from a firm part-owned by Abu Dhabi"s Mubadala Development Company, according to Arabian Business.
Privately held Proteus Digital Health, which is working with drugmakers including Novartis and Otsuka, said this week the funding was one of the biggest US private financings this year and the largest in the digital health sector and shows investor interest in its ingestible and wearable technology.
Proteus already has European and US approval for its "smart pill" technology system, in which a tiny sensor is embedded in a tablet and linked to a patch worn on the patient's abdomen.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.